ReviewCurrent atherosclerosis reports2016
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.
Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 53 citations in OpenAlex.
- Anti-obesity and metabolic benefits of metformin: Comparison of different delivery routes.Journal of drug delivery science and technology · 2024Article
- Obesity Management in Adults: A Review.JAMA · 2023 · on this mapReview
- Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study.Obesity science & practice · 2022Article
- Metformin Reduces Potassium Currents and Prolongs Repolarization in Non-Diabetic Heart.International journal of molecular sciences · 2022Article
- Transdermal Delivery of Metformin Using Dissolving Microneedles and Iontophoresis Patches for Browning Subcutaneous Adipose Tissue.Pharmaceutics · 2022Article
- Use of Weight Loss Medications in Patients after Bariatric Surgery.Current obesity reports · 2021Review
- Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit.Frontiers in endocrinology · 2021Review
- Utility of BMIQ, a novel web-based weight management programme, at an academic weight management centre.Obesity science & practice · 2020Article
- Article
- Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction.Current atherosclerosis reports · 2018Review
- Metformin Alters Gut Microbiota of Healthy Mice: Implication for Its Potential Role in Gut Microbiota Homeostasis.Frontiers in microbiology · 2018Article
- Review
- Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry.BMJ open diabetes research & care · 2017Article
- Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.PloS one · 2017Article
- Off-label drugs for weight management.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017Review
- Obesity Treatment at HealthPartners: Adaptation of Clinical Guidelines into Systems for Practice Operations.Current obesity reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment. Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety. Thus, metformin should be considered for a treatment indication in patients with these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.